Tuesday, 22 Sep 2026
Empowering Chinese Pharma’s Global Expansion
Contact US
Home
About US
Policy Hub
Categories
Drug
Company
Deals
Policy / Regulatory
Medical Device
R&D
Legal / IP
Digital
Privacy Policy
Contact US
My News
Cancer
Clinical trial approval / initiation
Product approvals
Finance
Clinical trial results
ADC / XDC
Finanical Reports
Biotech
Market approval filings
PD-1/L1
Read History
Search
Pages
Home
Blog Index
POLICY HUB
Contact Us
Personalized
Read History
Categories
Company
Drug
Policy / Regulatory
Medical Device
R&D
Digital
Legal / IP
Deals
Have an existing account?
Sign In
Follow US
Fineline Cube
Follow:
14455
Articles
Others
Xtalpi’s AI Biology Spin-off INFevo Secures Tens of Millions in Angel Funding to Build Virtual Cell System for Drug Discovery
June 3, 2026
Company
Drug
Roche’s Oral SERD Giredestrant Receives FDA Priority Review for Early Breast Cancer Adjuvant Treatment
June 3, 2026
Others
CSPC Pharmaceutical Receives NMPA Approval for First-in-Class mRNA-LNP Dual-Target CAR-T Therapy SYS 6063 in Systemic Lupus Erythematosus
June 3, 2026
Company
Drug
AstraZeneca’s Next-Gen SERD Camizestrant Shows 55% Reduction in Progression Risk and Superior ctDNA Clearance in Phase III SERENA-6 Trial
June 3, 2026
Company
Drug
SystImmune and Bristol Myers Squibb’s Dual-Targeted ADC Izalontamabbrengitecan Shows Significant Survival Benefit in Two Phase III Trials
June 3, 2026
Company
Drug
CSPC Pharmaceutical’s B7-H3 ADC SYS 6043 Shows 41.8% Response Rate in Phase I Solid Tumor Study
June 3, 2026
Policy / Regulatory
China’s NMPA Introduces Comprehensive Medical Device Classification Reforms with 2-5 Year Transitional Periods
June 2, 2026
Company
Deals
Rallybio to Merge with Avenzo Therapeutics in $215 Million Deal, Creating Pipeline-Rich Entity Focused on Chinese-Origin Oncology Assets
June 2, 2026
Company
Deals
Simcere Pharmaceutical Secures Exclusive Rights to PrimeGenX’s Pumecitinib Gel for Atopic Dermatitis in Greater China
June 2, 2026
Company
Drug
Amgen’s Tarlatamab Receives EC Approval for Extensive-Stage SCLC with 40% Mortality Reduction in Phase III Trial
June 2, 2026
Company
Deals
Servier Group Acquires Edgewise Therapeutics’ Muscular Dystrophy Business for Up to $2.65 Billion
June 2, 2026
Company
Drug
Alphamab Oncology’s HER3×TROP2 Bispecific ADC JSKN016 Shows 64.5% Response Rate in Triple-Negative Breast Cancer at ASCO 2026
June 2, 2026
1
2
…
77
78
79
80
81
…
1,204
1,205
Welcome to Fineline Cube!
Username or Email Address
Password
Remember me
Lost your password?